Nectar Lifesciences Q3 Result 2024: Date and Time, Share Price and Target

News: In this article, we’ll delve into the Q3 results of Nectar Lifesciences, a pharmaceutical company. We’ll explore the key details, including the date and time of the announcement, the share price, and the target outlook.

1. Date and Time of Q3 Results Announcement

Nectar Lifesciences is scheduled to reveal its quarterly results on February 14, 2024. Investors and stakeholders eagerly await this update to assess the company’s financial performance.

2. Share Price Insights

As of February 9, 2024, Nectar Lifesciences’ share price stands at ₹36.30 on the National Stock Exchange (NSE). This reflects a 3.97% decline from the previous closing price of ₹37.80. The stock has been volatile, and investors should keep a close eye on any further movements.

3. Target Analysis

While we don’t have specific target information for Q3 2024, it’s essential to consider the company’s overall performance. Factors such as revenue growth, cost management, and market trends play a crucial role in determining future targets.

4. Financial Metrics

• PE Ratio: Nectar Lifesciences currently has a negative PE ratio of -293.38.
• Earnings per Share (EPS): The trailing twelve months (TTM) EPS is ₹-0.12.
• Market Capitalization (MCap): The company’s MCap stands at ₹814.07 crore.
• Price-to-Book (PB) Ratio: The PB ratio is 0.80.
• Dividend Yield: Currently, there is no dividend yield.
• Beta: The stock’s beta indicates moderate volatility.

5. Shareholding Pattern

As of December 31, 2023, the shareholding pattern includes:

• Promoters: 55.80%
• Pledged Shares: 100.00%
• Foreign Institutional Investors (FII): 16.12%
• Domestic Institutional Investors (DII): 0.00%
• Mutual Funds: 0.00%
• Others: 28.08%

Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.

About Nectar Lifesciences Company :

Nectar Lifesciences Limited is a research-driven pharmaceutical company based in India. Let’s explore some key details about this company:

1. Company Overview:

• Nectar Lifesciences is a leading global manufacturer of cephalosporin antibiotics. These life-saving medicines are distributed in over 45 countries.
• The company has a strong presence in the pharmaceutical industry and offers a wide range of products, including Active Pharmaceutical Ingredients (API), intermediates, and finished dosage forms.

2. Cephalosporins Focus:

• Nectar Lifesciences specializes in the production of anti-infectives, particularly cephalosporins. These drugs play a crucial role in treating various infections.
• The company has earned a reputation as a reliable Contract Manufacturing Organization (CMO) for global pharma innovators.

3. Manufacturing Excellence:

• Nectar Lifesciences boasts world-class manufacturing facilities spread across 400,000 square meters near Chandigarh, nestled in the foothills of the Himalaya mountains (Punjab & Himachal Pradesh, India).
• The company has received approvals from regulatory bodies such as USFDA, EUGMP, PMDA, and KFDA.

4. Product Portfolio:

Nectar Lifesciences has significant capacities in producing cephalosporin antibiotics, including:

• Cefixime
• Cefuroxime Axetil (Amorphous and Crystalline)
• Cefotaxime Sodium
• Ceftriaxone Sodium

5. Quality and Sustainability:

• The company adheres to high-quality standards, with certifications including ISO 9001 QMS, ISO 14001 EMS, ISO 18001 OHSAS, ISO 50001 EnMS, ISO 13485, FSSC 22000, HACCP, BRC, and FSSAI.
• Nectar Lifesciences is committed to sustainability and operates a 12 MW clean captive power generation plant.
• Additionally, they run the Nectar Polytechnic, contributing to education and empowerment.

Investors should closely monitor Nectar Lifesciences’ Q3 results and consider the broader market context. While the share price has seen fluctuations, a comprehensive analysis will provide insights into the company’s future prospects.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.